Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Histological examination confirmed a wild-type (WT) IDH1/2, MGMT (DNA repair enzyme O6-methylguanine-DNA methyltransferase) methylated glioblastoma with a proliferative index focally as high as 20%.
|
31173153 |
2020 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter hypermethylation was detected in 38.7% of glioblastoma patients.
|
31701343 |
2020 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The CpG methylation status of the MGMT promoter strongly correlates with clinical outcome and, therefore, is used as prognostic marker during glioblastoma therapy.
|
31395346 |
2020 |
Adult Glioblastoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Characterization of MGMT and EGFR protein expression in glioblastoma and association with survival.
|
31823165 |
2020 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
In addition to its benefits for molecular subgrouping and copy number analysis of brain tumors, DNA-methylation based classification is a highly reliable tool for the assessment of MGMT promoter methylation status in glioblastoma patients.
|
31784096 |
2020 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The purpose of this study was to determine the effect of disulfiram (DSF), an aldehyde dehydrogenase inhibitor, on in vitro radiosensitivity of glioblastoma cells with different methylation status of O6-methylguanine-DNA methyltransferase (MGMT) promoter and the underlying mechanism of such effect.
|
30121967 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Exploring this novel combined approach in the clinic to treat glioblastoma patients with MGMT promoter-unmethylated tumors is warranted.
|
30537486 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The repair enzyme O6-methylguanine-DNA-methyltransferase (MGMT) is a validated predictor of benefit from temozolomide (TMZ) in glioblastoma.
|
30579113 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Clinical data (age, sex, extent of surgical resection), O6-methylguanine-DNA methyltransferase (MGMT) promoter methylation status and pre-operative T2WI of 113 pathologically confirmed glioblastoma patients (from our institution, n = 61; from the Cancer Imaging Archive, n = 52) were retrospectively reviewed.
|
31150499 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
O<sup>6</sup>-methylguanine-DNA-methyltransferase immunostaining intensity in glioblastoma.
|
29153917 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Although the two classical molecular markers of glioblastoma including isocitrate dehydrogenase 1 or 2 (IDH1/2) mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation are associated with overall survival rate of glioblastoma patients, they are not specific to the survival outliers.
|
31159876 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
The absence of systematic and clinically relevant changes in HRQOL and neurocognitive function combined with the survival benefit of lomustine-temozolomide versus temozolomide alone suggests that a long-term net clinical benefit exists for patients with newly diagnosed glioblastoma with methylation of the MGMT promoter and supports the use of lomustine-temozolomide as a treatment option for these patients.
|
31488360 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Studies examining the synergy between Dihydrotanshinone and Temozolomide against MGMT+ glioblastoma cells in vitro: Predicting interactions with the blood-brain barrier.
|
30399573 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, because temozolomide did not cause phosphorylation of cPLA<sub>2</sub> in MGMT high-expressing glioblastoma T98G cells, phosphorylation of cPLA<sub>2</sub> may be caused by DNA alkylation of temozolomide.
|
31442413 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Posttreatment Effect of MGMT Methylation Level on Glioblastoma Survival.
|
31058280 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
GTR and MGMT promoter methylation are independent prognosticators for improved overall and progression-free survival in a homogeneous cohort of newly diagnosed patients with IDH wild-type glioblastoma.
|
29617848 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Methylation of the O(6)-Methylguanine-DNA methyltransferase (MGMT) promoter is predictive for treatment response in glioblastoma patients.
|
31167648 |
2019 |
Adult Glioblastoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.
|
31413318 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
MGMT promoter methylation status testing to guide therapy for glioblastoma: refining the approach based on emerging evidence and current challenges.
|
30189035 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Data from a previous unrandomised phase 2 trial suggested that lomustine-temozolomide plus radiotherapy might be superior to temozolomide chemoradiotherapy in newly diagnosed glioblastoma with methylation of the MGMT promoter.
|
30782343 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To determine whether there is a threshold for the TMZ-induced DNA damage response and exploring the factors regulating the switch between p53 dependent survival and death, the glioblastoma lines LN-229 (deficient in MGMT) and LN-229MGMT (stably transfected with MGMT) were exposed to different doses of TMZ. p53 protein expression and phosphorylation levels of p-p53ser15 and p-p53ser46 were determined by Western blotting.
|
30925722 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Patients with glioblastoma without O6-methylguanine-DNA methyltransferase (MGMT) promoter hypermethylation are unlikely to benefit from alkylating chemotherapy with temozolomide (TMZ).
|
30277538 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epigallocatechin Gallate Preferentially Inhibits O<sup>6</sup>-Methylguanine DNA-Methyltransferase Expression in Glioblastoma Cells Rather than in Nontumor Glial Cells.
|
30558449 |
2019 |
Adult Glioblastoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our study offers novel insights for improving therapeutic management of MGMT-deficient glioblastoma.
|
31347685 |
2019 |
Adult Glioblastoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Enrichment analyses of intragenic DNA methylation profiles with epigenetic signatures prioritized the intragenic DNA methylation of ZMIZ1 as a possible glioblastoma prognostic marker that is independent of MGMT methylation in IDH1 wild-type patients.
|
31373686 |
2019 |